Clofarabine
- Generic Name
- Clofarabine
- Brand Names
- Clolar, Evoltra
- Drug Type
- Small Molecule
- Chemical Formula
- C10H11ClFN5O3
- CAS Number
- 123318-82-1
- Unique Ingredient Identifier
- 762RDY0Y2H
- Background
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
- Indication
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Associated Conditions
- Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
- Associated Therapies
- -
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT02425904
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇦The Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT
- Conditions
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 6
- Registration Number
- NCT02349178
- Locations
- 🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States
🇺🇸American Family Children's Hospital, Madison, Wisconsin, United States
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
- Conditions
- Acute Undifferentiated LeukemiaAcute Leukemia of Ambiguous LineageMixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise SpecifiedMixed Phenotype Acute LeukemiaMixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise SpecifiedAcute Bilineal LeukemiaAcute Biphenotypic LeukemiaRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02135874
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaAdult Acute Myeloblastic Leukemia With Maturation (M2)
- Interventions
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 727
- Registration Number
- NCT02085408
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
- Conditions
- Interventions
- Procedure: Allogeneic Bone Marrow TransplantationProcedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: Anti-Thymocyte GlobulinDrug: BusulfanDrug: ClofarabineDrug: Fludarabine PhosphateProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Vorinostat
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT02083250
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 2
- Registration Number
- NCT01960387
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2017-03-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT01900509
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT01885689
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- New York Medical College
- Target Recruit Count
- 41
- Registration Number
- NCT01842672
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Levine Children's Hospital, Charlotte, North Carolina, United States
Clofarabine for Langerhans in Pedi
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT01796405
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.